{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:30:06Z","timestamp":1790289006978,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To estimate the incidence of gestational trophoblastic neoplasia following complete and partial molar pregnancy after reaching normal human chorionic gonadotropin (hCG) levels to guide evidence-based follow-up recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>MEDLINE, EMBASE, Web of Science, POPLINE, Cochrane, and ClinicalTrials.gov were searched from inception to November 2018, using the intersection of \u201cgestational trophoblastic disease,\u201d \u201cmolar pregnancy,\u201d and \u201chuman chorionic gonadotropin\u201d themes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS OF STUDY SELECTION:<\/jats:title>\n                    <jats:p>Search results were screened to identify cohort studies of molar pregnancy reporting gestational trophoblastic neoplasia development, with at least 6 months of intended normal hCG follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TABULATION, INTEGRATION, AND RESULTS:<\/jats:title>\n                    <jats:p>\n                      Two reviewers independently identified articles for inclusion. Data were extracted using a standardized form. For meta-analysis, cumulative incidence of gestational trophoblastic neoplasia, with CIs by the Agresti-Coull method, and pooled risk ratios (RRs) comparing complete and partial mole were calculated. Among the 19 eligible studies that reported adequate data for inclusion in the primary meta-analysis, we found low incidence of gestational trophoblastic neoplasia after normal hCG level following both complete mole (64\/18,357, 0.35%, 95% CI 0.27\u20130.45%), and partial mole (5\/14,864, 0.03%, 95% CI 0.01\u20130.08%). There was a significantly higher risk of gestational trophoblastic neoplasia after complete compared with partial molar pregnancy (RR 4.72, 95% CI 1.81\u201312.3,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.002). Among gestational trophoblastic neoplasia cases after normal hCG level following complete mole, 89.6% occurred when the time from evacuation to normalization was 56 days or longer, and 60.7% were diagnosed beyond the commonly recommended 6-month surveillance interval. Sensitivity analyses, including those limiting to studies at low risk of bias, did not significantly affect results. We found an overall incidence of gestational trophoblastic neoplasia of 15.7% for complete mole (1,354\/8,611, 95% CI 15.0\u201316.5%) and 3.95% for partial mole (221\/5,593, 95% CI 3.47\u20134.50%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Gestational trophoblastic neoplasia development after normal hCG level following molar pregnancy is rare. Recommendations for frequency and duration of hCG follow-up can be minimized to lessen burden on patients and informed by the type of molar pregnancy and time interval from uterine evacuation to hCG normalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SYSTEMATIC REVIEW REGISTRATION:<\/jats:title>\n                    <jats:p>PROSPERO, CRD42019116414.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000003566","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T14:51:58Z","timestamp":1575643918000},"page":"12-23","source":"Crossref","is-referenced-by-count":64,"title":["Gestational Trophoblastic Neoplasia After Human Chorionic Gonadotropin Normalization Following Molar Pregnancy"],"prefix":"10.1097","volume":"135","author":[{"given":"Benjamin B.","family":"Albright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade M.","family":"Shorter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon A.","family":"Mastroyannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney A.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Sonalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ygyno.2008.09.005","article-title":"Current management of gestational trophoblastic diseases","volume":"112","author":"Berkowitz","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMcp0900696","article-title":"Molar pregnancy","volume":"360","author":"Berkowitz","year":"2009","journal-title":"N Engl J Med"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ajog.2010.06.073","article-title":"Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole","volume":"203","author":"Lurain","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/00006250-200406000-00051","article-title":"Diagnosis and treatment of gestational trophoblastic disease. ACOG Practice Bulletin No. 53. American College of Obstetricians and Gynecologists","volume":"103","year":"2004","journal-title":"Obstetrics Gynecol"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ijgo.12615","article-title":"Update on the diagnosis and management of gestational trophoblastic disease","volume":"143","author":"Ngan","year":"2018","journal-title":"Int J Gynecol Obstet"},{"key":"R7-20230711","first-page":"940","article-title":"Poor compliance with postmolar surveillance and treatment protocols by indigent women","volume":"96","author":"Massad","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ygyno.2005.01.015","article-title":"The impact of molar pregnancy on psychological symptomatology, sexual function, and quality of life","volume":"97","author":"Petersen","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/IGC.0b013e31820156d8","article-title":"What do women with gestational trophoblastic disease understand about the condition?","volume":"21","author":"Stafford","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"R10-20230711","first-page":"47","article-title":"Psychologic impact of follow-up after low-risk gestational trophoblastic disease","volume":"56","author":"Lok","year":"2011","journal-title":"J Reprod Med"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat Sci"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.AOG.0000136099.21216.45","article-title":"Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy","volume":"104","author":"Wolfberg","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/2230-8229.189129","article-title":"Clinical presentation and treatment outcome of molar pregnancy: ten years experience at a tertiary care hospital in Dammam, Saudi Arabia","volume":"23","author":"Al-Talib","year":"2016","journal-title":"J Family Community Med"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ygyno.2011.05.035","article-title":"Predicting gestational trophoblastic neoplasia (GTN): is urine hCG the answer?","volume":"122","author":"Alazzam","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0301-2115(03)00274-4","article-title":"How long should patients be followed after molar pregnancy? Analysis of serum hCG follow-up data","volume":"112","author":"Batorfi","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2015.09.012","article-title":"Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation","volume":"139","author":"Braga","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2017.12.008","article-title":"What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients","volume":"148","author":"Coyle","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R23-20230711","first-page":"925316","article-title":"Incidence, management, and outcome of molar pregnancies at a tertiary care hospital in Quetta, Pakistan","volume":"2011","author":"Fatima","year":"2011","journal-title":"ISRN Obstet Gynecol"},{"key":"R24-20230711","first-page":"732","article-title":"Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation","volume":"101","author":"Feltmate","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/1471-0528.12742","article-title":"Gestational trophoblastic neoplasia after achieving a nondetectable serum human chorionic gonadotrophin level","volume":"121","author":"Gueye","year":"2014","journal-title":"BJOG"},{"key":"R26-20230711","first-page":"192","article-title":"Follow-up after molar pregnancy evacuation: feasibility of using semi-quantitative urine pregnancy tests","volume":"61","author":"Hoppenot","year":"2016","journal-title":"J Reprod Med"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejogrb.2006.01.024","article-title":"Clinicopathologic characteristics and subsequent pregnancy outcome in 139 complete hydatidiform moles","volume":"128","author":"Horn","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2007.03.010","article-title":"Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands","volume":"106","author":"Kerkmeijer","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R29-20230711","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.ajog.2004.12.080","article-title":"Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles","volume":"192","author":"Lavie","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"R30-20230711","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/humrep\/16.6.1274","article-title":"Subsequent pregnancy outcome in patients with spontaneous resolution of HCG after evacuation of hydatidiform mole: comparison between complete and partial mole","volume":"16","author":"Matsui","year":"2001","journal-title":"Hum Reprod"},{"key":"R31-20230711","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/01443615.2012.741150","article-title":"Outcome of molar pregnancies in Malaysia: a tertiary centre experience","volume":"33","author":"Nirmala","year":"2013","journal-title":"J Obstet Gynaecol"},{"key":"R32-20230711","doi-asserted-by":"crossref","first-page":"321","DOI":"10.59566\/IJBS.2009.5321","article-title":"Clinical analysis and management of gestational trophoblastic diseases: a 90 cases study","volume":"5","author":"Riadh","year":"2009","journal-title":"Int J Biomed Sci"},{"key":"R33-20230711","first-page":"478","article-title":"Prognostic characteristics of serum human chorionic gonadotropin titer regression following molar pregnancy","volume":"58","author":"Schlaerth","year":"1981","journal-title":"Obstet Gynecol"},{"key":"R34-20230711","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2013.03.010","article-title":"Risk of gestational trophoblastic neoplasia after hCG normalization according to hydatidiform mole type","volume":"130","author":"Schmitt","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R35-20230711","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/IGC.0000000000001374","article-title":"Gestational trophoblastic neoplasia from genetically confirmed hydatidiform moles: prospective observational cohort study","volume":"28","author":"Usui","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R36-20230711","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1479-828X.2006.00539.x","article-title":"Persistent trophoblast disease following partial molar pregnancy","volume":"46","author":"Wiesma","year":"2006","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R37-20230711","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1479-828X.2006.00538.x","article-title":"Guidelines following hydatidiform mole: a reappraisal","volume":"46","author":"Wiesma","year":"2006","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"R38-20230711","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.AOG.0000227754.12848.4e","article-title":"Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy","volume":"108","author":"Wolfberg","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R39-20230711","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1471-0528.2007.01320.x","article-title":"Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit","volume":"114","author":"Sebire","year":"2007","journal-title":"BJOG"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T03:28:29Z","timestamp":1722137309000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003566"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003566","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737043457.793575126","asserted-by":"object"}]},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,3]]}}}